Fosamax for Glucocorticoid-Induced Osteoporosis: Evidence Summary

Why Glucocorticoid-Induced Osteoporosis Demands Early Treatment

Glucocorticoids cause the most common form of secondary osteoporosis worldwide, and bone loss begins within the first three months of starting therapy. Roughly 30% to 50% of patients on long-term glucocorticoids will experience a fracture [1]. The mechanism is distinct from postmenopausal bone loss.

Glucocorticoids suppress osteoblast function and accelerate osteocyte apoptosis, producing a rapid decline in bone formation that outpaces any concurrent increase in resorption [2]. Robert Weinstein, MD, wrote in the New England Journal of Medicine: "The predominant effect of glucocorticoids on the skeleton is a profound suppression of bone formation" [2]. This pathophysiology explains why GIO fractures occur at higher BMD thresholds than primary osteoporosis. A patient on 7.5 mg of prednisone daily fractures at a T-score that would be classified as osteopenia in an untreated individual [3].

The speed of bone loss matters. Trabecular bone density can drop 6% to 12% in the first year of glucocorticoid therapy [1]. Vertebral compression fractures may appear within six months. Because the fracture risk rises before DXA scores fall into the "osteoporotic" range, the ACR 2017 guideline recommends initiating bone-protective therapy based on glucocorticoid dose and duration rather than waiting for a T-score of -2.5 [3].

Is Alendronate Actually Off-Label for GIO?

No. This is a common misconception. The FDA approved alendronate for the treatment and prevention of glucocorticoid-induced osteoporosis in 1999, making it one of the few bisphosphonates with a specific GIO label indication [4].

The confusion likely arises because many clinicians associate Fosamax primarily with postmenopausal osteoporosis, its original 1995 indication. The GIO approval came four years later, based on the Saag et al. key trial [5]. The Fosamax prescribing information lists four distinct approved indications: postmenopausal osteoporosis (treatment and prevention), male osteoporosis, Paget's disease, and glucocorticoid-induced osteoporosis (treatment and prevention) [4].

Why does the distinction matter? Off-label use can complicate insurance coverage and medicolegal positioning. Prescribers who document GIO as the indication can cite the FDA-approved label directly, avoiding prior authorization hurdles that apply to genuinely off-label prescriptions. For patients searching "off-label Fosamax for steroid osteoporosis," the answer is simpler than expected: this is an on-label, guideline-endorsed use.

The Saag 1998 Key Trial

The foundational evidence comes from a 48-week, randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine by Kenneth Saag and colleagues [5]. The study enrolled 477 men and women (ages 17 to 83) who had received at least 7.5 mg of prednisone or equivalent daily for a minimum of three months.

Participants received alendronate 5 mg/day, alendronate 10 mg/day, or placebo. All groups received calcium (800 to 1,000 mg) and vitamin D (250 to 500 IU) supplementation. The primary endpoint was change in lumbar spine BMD at 48 weeks [5].

Results were unambiguous. The alendronate 10 mg group gained 2.1% lumbar spine BMD versus a 0.4% loss in the placebo arm (P<0.001) [5]. Femoral neck BMD increased 1.2% with alendronate 10 mg versus a 1.0% decline with placebo. The 5 mg dose produced intermediate gains. Vertebral fracture incidence was lower in the alendronate groups, though the study was not powered to detect fracture reduction as a primary outcome [5].

The two-year extension (Adachi et al., 2001) confirmed durability. At 24 months, lumbar spine BMD had increased 3.0% with alendronate 10 mg from baseline, and the fracture reduction reached statistical significance: new vertebral fractures occurred in 0.7% of alendronate-treated patients versus 6.8% of placebo-treated patients (P=0.026) [6].

Head-to-Head Comparisons With Other GIO Therapies

Alendronate is not the only option. Several trials have compared it against other bone-protective agents in GIO populations, producing a clearer picture of where it fits in the treatment hierarchy.

Alendronate vs. alfacalcidol. De Nijs et al. (2006) randomized 201 patients with GIO to alendronate 10 mg/day or alfacalcidol 1 mcg/day for 18 months. Alendronate produced a 2.1% gain in lumbar spine BMD versus 0.5% with alfacalcidol (P<0.001), and the number of patients with new vertebral fractures was significantly lower in the alendronate arm (one patient vs. eight patients, P=0.02) [7].

Alendronate vs. risedronate. Both are oral bisphosphonates with GIO indications. Direct comparison data are limited, but the 2017 ACR guideline treats them as clinically equivalent for GIO and does not prefer one over the other [3].

Oral bisphosphonates vs. IV zoledronic acid. The HORIZON-GIO trial (Reid et al., 2009) randomized 833 GIO patients to zoledronic acid 5 mg IV annually versus risedronate 5 mg daily. Zoledronic acid produced greater lumbar spine BMD gains at 12 months (4.1% vs. 2.7% in the treatment subgroup, P<0.001) [8]. While this trial compared zoledronic acid to risedronate rather than alendronate, it suggests that IV bisphosphonates may offer a BMD advantage at the cost of infusion-related adverse events (fever, myalgia in roughly 15% of first infusions).

Bisphosphonates vs. teriparatide. Because GIO is primarily a disease of suppressed bone formation, anabolic therapy has theoretical appeal. Saag et al. (2007) compared teriparatide 20 mcg/day to alendronate 10 mg/day in 428 GIO patients over 18 months. Teriparatide produced greater lumbar spine BMD gains (7.2% vs. 3.4%, P<0.001) and fewer new vertebral fractures (0.6% vs. 6.1%, P=0.004) [9]. The ACR guideline conditionally recommends teriparatide over oral bisphosphonates only for patients at very high fracture risk, given its higher cost and injectable route [3].

What the ACR 2017 Guideline Recommends

The 2017 American College of Rheumatology guideline stratifies GIO management by fracture risk category (low, moderate, high) and glucocorticoid dose [3]. Its recommendations for adults aged 40 and older who are starting or already receiving glucocorticoids at any dose for three months or longer are specific.

For moderate-to-high fracture risk patients, the guideline conditionally recommends oral bisphosphonates (alendronate, risedronate, or zoledronic acid) over no treatment, calcium and vitamin D alone, or calcitonin [3]. Lori Buckley, PhD, the guideline's lead author, stated: "We conditionally recommend treatment with an oral bisphosphonate over no additional treatment for patients at moderate-to-high fracture risk" [3].

For high and very high fracture risk patients, IV zoledronic acid or teriparatide may be preferred over oral bisphosphonates when adherence to daily/weekly oral dosing is a concern or when fracture risk is especially elevated [3]. Denosumab is also conditionally recommended, though it carries a rebound vertebral fracture risk upon discontinuation that complicates its use in GIO.

An important distinction: the ACR guideline recommends starting bone-protective therapy as soon as long-term glucocorticoids (defined as three or more months at any dose) are initiated, rather than waiting for bone density testing. This aggressive posture reflects the speed at which GIO develops [3].

Dosing and Administration for GIO

Alendronate dosing for GIO follows the same administration rules as for postmenopausal osteoporosis, with one key difference in the dose for prevention versus treatment [4].

For GIO prevention (patients starting glucocorticoids who do not yet have osteoporosis), the approved dose is 5 mg daily or 35 mg weekly. For GIO treatment (patients with established osteoporosis or fragility fracture), the dose is 10 mg daily or 70 mg weekly [4]. Postmenopausal women not on estrogen should use the treatment dose regardless of T-score [4].

Administration requires strict adherence to the esophageal safety protocol. Patients take the tablet first thing in the morning with 6 to 8 ounces of plain water, on an empty stomach, and remain upright for at least 30 minutes before eating or drinking anything else [4]. Non-compliance with these instructions is the primary driver of esophageal adverse events (esophagitis, erosion, rarely perforation). Co-administration with calcium, antacids, or other medications reduces bioavailability to near zero [4].

All GIO patients should receive supplemental calcium (1,000 to 1,200 mg daily) and vitamin D (600 to 800 IU, adjusted to maintain serum 25(OH)D above 20 ng/mL) as baseline therapy [10]. Alendronate is added on top of this supplementation, not as a replacement for it.

Who Should and Should Not Receive Alendronate for GIO

Patient selection requires attention to renal function, gastrointestinal history, and fracture risk severity. The prescribing label contraindicates alendronate in patients with esophageal abnormalities that delay emptying (stricture, achalasia), inability to stand or sit upright for 30 minutes, hypocalcemia, or creatinine clearance below 35 mL/min [4].

GIO populations often overlap with rheumatologic or pulmonary disease patients who take multiple medications. Drug interactions are minimal for alendronate itself, but timing conflicts are common. Proton pump inhibitors, which many glucocorticoid users take for gastroprotection, should be separated by at least 30 minutes from the bisphosphonate dose [4].

Premenopausal women of childbearing potential present a clinical gray area. Bisphosphonates have long skeletal half-lives (alendronate remains in bone for an estimated 10 years after discontinuation) and animal data show fetal toxicity at high doses [4]. The ACR guideline conditionally recommends oral bisphosphonates for premenopausal women at moderate-to-high fracture risk only after discussing the theoretical reproductive risks, and effective contraception should be in place during treatment [3].

For patients who cannot tolerate oral bisphosphonates, IV zoledronic acid, denosumab, or teriparatide are alternatives. The choice depends on fracture risk severity, cost, and whether the patient can commit to the monitoring requirements (especially for denosumab, which requires uninterrupted dosing to prevent rebound fractures) [3].

Monitoring and Duration of Therapy

There is no fixed stopping rule for alendronate in GIO that mirrors the "bisphosphonate holiday" concept used in primary osteoporosis. The rationale is straightforward: as long as the glucocorticoid exposure continues, the skeletal insult continues [3].

DXA monitoring should occur at baseline and every one to two years during glucocorticoid therapy [3]. A decline in BMD of 10% or more per year despite alendronate therapy should trigger reassessment: verify medication adherence, check for secondary causes of bone loss (vitamin D deficiency, hypogonadism, hyperparathyroidism), and consider switching to IV zoledronic acid or teriparatide [3].

When glucocorticoids are tapered and discontinued, the need for ongoing bisphosphonate therapy should be re-evaluated. Patients who have achieved a stable or improved T-score and are no longer on glucocorticoids may be candidates for discontinuation, though those with prior fragility fracture generally warrant continued treatment or close surveillance [10].

Bone turnover markers (CTX, P1NP) can supplement DXA in assessing treatment response, though they are not required by guidelines. A persistently elevated CTX despite oral bisphosphonate therapy may indicate poor absorption or non-adherence rather than treatment failure [10].

The most important clinical instruction: do not delay. If a patient will receive prednisone 2.5 mg or more daily for three months or longer and has a moderate or high FRAX-based fracture probability, start alendronate (or an equivalent bisphosphonate) concurrently with the glucocorticoid prescription [3].